Sodium Bicarbonate
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Sodium Bicarbonate
- Sodium Bicarbonate: From Antacid and Acid-Base Correction to Bronchitis (Top TxGNN Prediction)
Sodium Bicarbonate: From Antacid and Acid-Base Correction to Bronchitis (Top TxGNN Prediction)
One-Sentence Summary
Sodium bicarbonate is an alkalinising agent and antacid, marketed in Singapore as injections, haemodialysis powders, capsules and antacid products. The TxGNN model's top prediction is bronchitis, but there are no clinical trials and only 1 publication (a 1976 physiology study that does not address bronchitis treatment) behind it. The best-supported signals are in the lower-ranked anaphylaxis (exercise-induced) predictions, which rest on two small, old case-level reports.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the available licence data (products are listed as injection, haemodialysis powder, capsule, antacid suspension/powder/tablet and granule) |
| Predicted New Indication | Bronchitis |
| TxGNN Prediction Score | 97.91% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, sodium bicarbonate is a bicarbonate buffer used to neutralise acid (gastric acid in antacid products, metabolic acid in intravenous use, and as a dialysis buffer).
For bronchitis, no clear mechanistic link was found. The only retrieved paper (PMID 778960, 1976) examines pulmonary vascular responses to hypercapnic ventilation, not bronchitis treatment. The high score is a model prediction without clinical support.
Other predictions have somewhat more context:
- Anaphylaxis / food-dependent exercise-induced anaphylaxis: Two small clinical reports (1986, 1992) describe sodium bicarbonate pretreatment inhibiting exercise-induced and wheat-dependent exercise-induced anaphylaxis. A proposed explanation is that bicarbonate buffers exercise-related acid-base shifts that favour mast cell activation. This is not established, and the evidence is limited to this subtype. In other anaphylaxis papers, bicarbonate is only supportive care for shock or resuscitation.
- Open-angle glaucoma: The link is genetic only (the bicarbonate cotransporter gene SLC4A10 and AQP1 as candidate genes). It does not show that systemic sodium bicarbonate is therapeutic.
- Irritable bowel syndrome: Speculative, based on possible effects on luminal pH and ion transport.
- Hyperthyroidism: Bicarbonate appears only as supportive care for complications such as metabolic acidosis and rhabdomyolysis.
- Resistance to thyroid hormone, primary hereditary glaucoma, hyperthyroxinemia, esotropia: No mechanistic rationale or clinical evidence found.
Clinical Trial Evidence
For the top prediction (bronchitis): Currently no related clinical trials registered.
For lower-ranked predictions, only one trial was found, for irritable bowel syndrome:
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00796354 | Phase 3 | Completed | 210 | Multi-centre, double-blind, placebo-controlled study of Movicol® in constipation associated with IBS. Nothing confirms that sodium bicarbonate is the intervention, so it should not be counted as supporting evidence until verified. |
Literature Evidence
For bronchitis (rank 1):
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 778960 | 1976 | Physiology study | Respiration | Hypercapnic ventilation (5% CO2) raised pulmonary artery pressure and vascular resistance. Not a study of bronchitis treatment. |
Most relevant literature for other predicted indications (for context):
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 3024520 | 1986 | Clinical study / case report | Allergy | Exercise-induced anaphylaxis inhibited with sodium bicarbonate |
| 1310835 | 1992 | Case report | Annals of Allergy | Bicarbonate pretreatment prevented recurrence of wheat-dependent exercise-induced anaphylaxis and blunted the pH drop |
| 22233286 | 2012 | Review | BJU International | In interstitial cystitis, questionnaire data suggest sodium bicarbonate may improve symptoms (not IBS) |
| 20101282 | 2010 | Genetic association | Molecular Vision | SLC4A10 (bicarbonate transporter) and AQP1 as candidate genes for primary open-angle glaucoma |
| 34239739 | 2021 | Case report | Case Reports in Endocrinology | Hypokalaemic periodic paralysis with thyrotoxicosis and renal tubular acidosis |
Singapore Market Information
There are 20 valid licences, all single-ingredient. The approved indication text is not available in the licence data. Main authorisations:
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN09226P | Sodium Bicarbonate Intravenous Infusion 8.4% w/v | Injection | Not stated |
| SIN09851P | Sodium Bicarbonate Intravenous Infusion BP 4.2% w/v | Injection | Not stated |
| SIN05414P | Sodium Bicarbonate Capsule 500 mg | Capsule | Not stated |
| SIN13822P | BIBAG (5008 Design) Powder for Haemodialysis | Powder, for solution | Not stated |
| SIN14016P | Gaviscon Double Action Liquid | Suspension | Not stated |
Other products include Bicart and BIBAG haemodialysis powders, further Gaviscon products, Aromag, Magtasil and Kaomix antacid mixtures, Ohta's Isan antacid powder, E-Z-Gas II granules, Inon granules, Gascovid liquid and Ural effervescent granules.
Safety Considerations
Drug Interactions (100 interactions recorded; examples):
- Moderate: doxycycline, tetracycline, minocycline, acetylsalicylic acid, atropine, bisacodyl, chlorpropamide, acetohexamide, glipizide, ephedrine, pancrelipase
- Minor: famotidine, ranitidine, cimetidine, hydrocortisone, dexamethasone, betamethasone, triamcinolone, misoprostol
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (bronchitis) has no clinical trials and no supporting literature, so it rests on a model score alone (L5). The most plausible signals are for exercise-induced anaphylaxis, but they come from two small, old, non-randomised reports in a narrow subtype and are best treated as a research question rather than a repurposing recommendation.
To proceed, the following is needed:
- Mechanism of action data (currently unavailable)
- Package insert warnings and contraindications (currently unavailable), required before any safety screening
- Approved indication text for the Singapore licences
- Manual verification of whether NCT00796354 involves sodium bicarbonate
- Confirmatory study design for exercise-induced anaphylaxis if that direction is pursued
- Route and formulation compatibility assessment for any proposed new indication
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.